Processa Pharmaceuticals Operating Income Over Time
| PCSA Stock | USD 2.10 0.18 7.89% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Processa Pharmaceuticals Performance and Processa Pharmaceuticals Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. Anticipated expansion of Processa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Processa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Processa Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Processa Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Processa Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Processa Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Processa Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Processa Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Processa Pharmaceuticals and related stocks such as Briacell Therapeutics, Curis Inc, and Entero Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCTX | (8.6 K) | (559.6 K) | (290.1 K) | (476.5 K) | (1.9 M) | (2.2 M) | (3.2 M) | (5 M) | (6.3 M) | (4.8 M) | (8.9 M) | (19.4 M) | (31.3 M) | (45.5 M) | (37.7 M) | (34 M) | (32.3 M) |
| CRIS | (13.9 M) | (7.2 M) | (18.6 M) | (9.4 M) | (15.9 M) | (56.5 M) | (58 M) | (49.8 M) | (29.3 M) | (24.4 M) | (24.9 M) | (42.1 M) | (53 M) | (48.3 M) | (44.5 M) | (40.1 M) | (42.1 M) |
| PALI | (1.6 M) | (13 M) | (10.2 M) | (12.5 M) | (17.4 M) | (19.2 M) | (20.2 M) | (13.2 M) | (8.3 M) | (8.6 M) | (9.3 M) | (41.9 M) | (15.7 M) | (13.1 M) | (14.9 M) | (13.4 M) | (14 M) |
| HOTH | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (2.5 M) | (7.7 M) | (7.3 M) | (14.1 M) | (11.1 M) | (7.7 M) | (8.2 M) | (7.4 M) | (7.8 M) |
| MBRX | (738.2 K) | (738.2 K) | (738.2 K) | (738.2 K) | (738.2 K) | (738.2 K) | (3.9 M) | (8.7 M) | (15 M) | (17.5 M) | (19.7 M) | (23 M) | (30.6 M) | (29.6 M) | (26.6 M) | (24 M) | (25.2 M) |
| ALLR | (81.2 K) | (81.2 K) | (81.2 K) | (81.2 K) | (68.7 K) | (1.4 M) | (4.5 M) | (3.8 M) | (5 M) | (17.6 M) | (8.3 M) | (26.6 M) | (34.5 M) | (17.1 M) | (27.2 M) | (24.5 M) | (23.3 M) |
| CTXR | (25.6 K) | (19.6 K) | (28.1 K) | (1.2 M) | (3.2 M) | (7.4 M) | (10 M) | (13.8 M) | (15.6 M) | (17.7 M) | (23.5 M) | (33.3 M) | (36.7 M) | (42 M) | (38.5 M) | (34.7 M) | (32.9 M) |
Processa Pharmaceuticals and related stocks such as Briacell Therapeutics, Curis Inc, and Entero Therapeutics Operating Income description
Operating Income is the amount of profit realized from Processa Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Processa Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Processa Pharmaceuticals | PCSA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 7380 Coca Cola |
| Exchange | NASDAQ Exchange |
USD 2.1
Check out Processa Pharmaceuticals Performance and Processa Pharmaceuticals Correlation. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Processa Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.